Hyaluronan in COVID-19 morbidity, a bedside-to-bench approach to understand mechanisms and long-term consequences of hyaluronan - Hellman, Urban; Rosendal, Ebba; Lehrstrand, Joakim; Henriksson, Johan; Björsell, Tove; Hahn, Max; Österberg, Björn; Dorofte, Luiza; Nilsson, Emma; Forsell, Mattias N.E.; Smed-Sörensen, Anna; Lange, Anna; et al. (medRxiv, 2023)
Background We have previously shown that lungs from deceased COVID-19 patients are filled with hyaluronan (HA). In this translational study, we investigated the role of HA in all stages of COVID-19 disease, to map the consequences of elevated HA in morbidity and identify the mechanism of SARS-CoV-2-induced HA production.Methods Lung morphology was visualized in 3D using light-sheet fluorescence microscopy. HA was verified by immunohistochemistry, and fragmentation was determined by gas-phase electrophoretic molecular mobility analysis. The association of systemic HA in blood plasma and disease severity was assessed in patients with mild (WHO Clinical Progression Scale, WHO-CPS, 1-5) and severe COVID-19 (WHO-CPS 6-9), during the acute and convalescent phases and related to lung function. In vitro 3D-lung models differentiated from primary human bronchial epithelial cells were used to study effects of SARS-CoV-2 infection on HA metabolism.Findings Lungs of deceased COVID-19 patients displayed reduced alveolar surface area compared to healthy controls. We verified HA in alveoli and showed high levels of fragmented HA both in lung tissue and aspirates. Systemic levels of HA were high during acute COVID-19 disease, remained elevated during convalescence and associated with reduced diffusion capacity. Transcriptomic analysis of SARS-CoV-2-infected lung models showed dysregulation of HA synthases and hyaluronidases, both contributing to increased HA in apical secretions. Corticosteroid treatment reduced inflammation and, also, downregulated HA synthases.Interpretation We show that HA plays a role in COVID-19 morbidity and that sustained elevated HA concentrations may contribute to long-term respiratory impairment. SARS-CoV-2 infection triggers a dysregulation of HA production, leading to increased concentrations of HA that are partially counteracted by corticosteroid treatment. Treatments directly targeting HA production and/or degradation can likely be used early during infection and may alleviate disease progression and prevent long-term lung complications.Competing Interest StatementA.L. has received unconditional research support from Carl Bennet AB. There are no patents, products in development or marketed products associated with this research to declare.Funding StatementThis study was supported by: the Swedish Heart-Lung Foundation (20200385 to A.K.Ö & A.L., 20200325 & 20210078 to C.A., and 20200366 & 20210049 to A.B.), SciLife Lab COVID-19 research program funded by the Knut and Alice Wallenberg Foundation (2020.0182 & C19R:028 to A.K.Ö. & A.L., and VC-2020-0015 to C.A.), Kempestiftelserna (grant no. JCK-1827 to A.K.Ö.), Ume a University and County Council of Västerbotten (#RV-938855 to C.A. and #RV-970074 to A.K.O.), Carl Bennet AB (A.L.), the Fundraising Foundation for Medical Research, Ume a University (978018 to A.L. and 964781 to U.H.), Nyckelfonden Örebro (OLL-938628, OLL-961416 to S.C.), Regional Research Council Mid Sweden (RFR-968856, RFR-940474 to S.C), the Swedish Research Council (2020-06235 to M.N.E.F, 2016-06514 to J.N., 2021-06602 to J.H.), J.N. is a Wallenberg Centre for Molecular Medicine Associated Researcher. Computations were performed using resources provided by SNIC through Uppsala Multidisciplinary Center for Advanced Computational Science (UPPMAX) under Project SNIC 2021/22-697 to J.H. Apart from funding, the sponsors were not involved in performing the present study.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical permission for the study was obtained by the Swedish Ethical Review Authority (no. 2020-01557 (original application), 2020-02870, 2020-05494. 2021-00353 (amendments)) and all research was carried out according to the Declaration of HelsinkiI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors